Enzymatica AB's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 19.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -13.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Enzymatica AB's EBIT per Share or its related term are showing as below:
FRA:EN9'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -614 Med: 4.2 Max: 36.7
Current: 19.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Enzymatica AB was 36.70% per year. The lowest was -614.00% per year. And the median was 4.20% per year.
FRA:EN9's 3-Year EBIT Growth Rate is ranked better than 67.9% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs FRA:EN9: 19.70
Enzymatica AB's EBIT for the
three
months ended in Mar. 2026 was €-1.23 Mil.
Enzymatica AB (FRA:EN9) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Enzymatica AB EBIT per Share Related Terms
Enzymatica AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB (FRA:EN9) has a EBIT per Share of €-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #260 out of 810 companies in the Drug Manufacturers industry, placing it in the top 32.1%.
Is Enzymatica AB's EBIT per Share too high?
Enzymatica AB's current EBIT per Share is €-0.02. Based on the distribution chart, Enzymatica AB ranks #260 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #260 out of 810 companies for EBIT per Share. This puts Enzymatica AB in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current EBIT per Share is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.20 — trading 22.2% above its estimated fair value. The current EBIT per Share is €-0.02. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current EBIT per Share is €-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.20 is trading 22.2% above its estimated GF Value™ of €0.16.
GuruFocus considers Enzymatica AB to be Modestly Overvalued.
Key valuation signals for FRA:EN9:
EBIT per Share: €-0.02
GF Value™: €0.16 vs. price of €0.20 (22.2% above fair value)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
36GF Score
Get the complete analysis for FRA:EN9
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
